List view / Grid view
The new data highlights the potential of the ItovebiTM (inavolisib)-based regimen as a new standard of care in advanced PIK3CA-mutated, HR-positive, HER2-negative breast cancer.
The Itovebi-based combination therapy was recently granted US FDA approval for a common metastatic breast cancer.
Certain breast cancer patients treated with Ibrance (palbociclib) and an aromatase inhibitor were significantly less likely to die than those treated with the inhibitor alone, according to real-world evidence.
NICE has approved palbociclib through the Cancer Drugs Fund, meaning that women with advanced breast cancer who have already received hormone therapy will now be eligible for palbociclib on the NHS.
Researchers have revealed the top 10 drugs by annual revenue in 2025. Here, we investigate the indications that necessitate these treatments and the delivery systems they employ.
